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Many pharmaceutical products ﬁnd their way into receiving waters, giving rise to concerns regarding
their environmental impact. A procedure was proposed that enables ranking of the hazard to aquatic
species and human health due to such products. In the procedure, hazard assessment is based on ﬁve of
the pharmaceutical product’s individual physico-chemical properties. These properties are aggregated
using the weighted Euclidian distance as the utility function. The weights and physico-chemical prop-
erties are considered as random variables. Physico-chemical property uncertainty criteria are obtained
from a literature review. Weight uncertainty is based on a hazard ranking from a panel of experts, the
histogram of which is converted into a continuous probability density function using statistical Kernel
smoothing technique. The hazard-ranking procedure was applied to a list of common pharmaceuticals
used in Switzerland. The procedure is target-speciﬁc. Two rankings were presented: One giving priority
to environmental protection and the other to human health. For most substances, the hazard rank
depends on the target. For the Swiss case study, the ranking procedure led to the conclusion that the
hormones ethinylestradiol and testosterone, along with the antibiotic erythromycin A, should be in all
cases included in risk-assessment methodologies, environmental concentration estimates and regular
measurement campaigns. The methodology proposed is ﬂexible and can be extrapolated to other
substances and groups of experts.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Pharmaceuticals in the environment can have adverse effects on
aquatic ecosystems (Kummerer, 2001) and on human health (Bruce
et al., 2010), so it is beneﬁcial to limit their presence in natural
waters (European Commission, 1996; WHO, 2008). At the same
time, human health mandates pharmaceutical usage, in which case
they will be supplied continually to the environment. In order
to avoid tradeoffs between human health and environmental
protection, it is important to estimate the hazard of environmen-
tally harmful pharmaceuticals so that their concentrations can be
limited, if necessary, in the natural world. For example, with
information on the relative hazard of pharmaceuticals, it is possible
to substitute some substances with others less hazardous to the
environment, whilst maintaining their therapeutic beneﬁts.nt GR), Station 2, Lausanne,
All rights reserved.A review of the literature shows that most studies deal with
estimation of pharmaceutical risk to the environment (Camacho-
Munõz et al., 2010; Cunningham et al., 2009; Enick and Moore,
2007, e.g.). Risk differs from hazard in that risk estimation
involves integration of the occurrence of the substance in the
environment, either directly using ﬁeld campaigns or indirectly
through the analysis of consumption data. There are several factors
that can cause inaccuracies in pharmaceutical risk calculations can
be subject to inaccuracy. First, there are many different patterns of
pharmaceutical prescription and consumption around the world,
and even within the same country, so transferring risk estimates
from one place to another is not automatic (Ternes and Joss, 2006).
Second, a common assumption is that drug sale volumes correlate
with environmental concentrations. In consequence, many studies
have used prescription amounts as a way to estimate environ-
mental risk (Carlsson et al., 2006; Cooper et al., 2008; Jones et al.,
2002; Perazzolo et al., 2010; Valcárcel et al., 2011). However,
Bisceglia and Roberts (2005) show that the total expenditure on
pharmaceuticals does not correlate with either usage or environ-
mental concentrations. Similarly, excretion factors are used to
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pharmaceutical substances (Besse and Garric, 2008; Perazzolo
et al., 2010). Yet, compounds with low excretion rates can also be
highly conservative in the environment, so estimates of concen-
trations based on excretion factors might also be poor predictors of
environmental risk. For instance, Jjemba (2006) has shown
that pharmaceutical concentrations in the environment correlate
negatively with the amount of the parent compound excreted.
Unlike risk, hazard is speciﬁc neither to time nor space (Ternes
and Joss, 2006). Rather, it refers to the physico-chemical charac-
teristics of the substance. Hazard studies thus allow different
substances to be comparedwith respect to their potential effects on
the environment. In so doing, pharmaceutical hazard assessments
are generic, and are a precursor to environmental risk assessments.
Relatively few studies focus on the hazard of chemical substances
(Lithner et al., 2011; Logue et al., 2011), and even fewer aim to esti-
mate the hazard of pharmaceuticals. Carlsson et al. (2006) estimated
the hazard of chemicals in a list of pharmaceuticals based on Euro-
pean legislation (Directive 67/548/EEC11). They allocated the
substances investigated into the binary categories: “Dangerous for
the environment” and “Not dangerous for the environment”. Hazard
evaluation is also emphasized in the REACHPBTapproach (European
Commission, 2006). This approach uses thresholds based on
different parameters that are proxies for the capacity of the chemical
to be persistent in (P), to bioaccumulate in (B), and to be toxic to (T)
the environment. The thresholds are then compared to assess when
the chemical should be classed as hazardous. Such concepts for drug
hazard assessment ﬁt under the rubric of EcoPharmacovigilance,
a discipline that seeks to evaluate adverse events related to drugs in
the ecosystem, taking into consideration all consequences to
humans and other organisms (Kummerer and Velo, 2006).
The aforementioned existing hazard evaluation methods iden-
tify drug groups of similar hazard levels. There are several issues to
note concerning their utility, however. First, they do not identify
whether a given substance is more hazardous to human health than
to the aquatic environment. Existing rankings are oriented towards
protection of either the aquatic environment or human health, with
no possibility to include tradeoffs between them. Second, they
do not allow ranking the hazard of different substances. Third,
uncertainties that can exist in the biochemical properties of indi-
vidual chemical compounds are not accounted for, as demonstrated
in various studies on the hazard of chemical substances (Tosato
et al., 1991) and pesticides (Newman, 1995). In addition, environ-
mental hazard studies necessarily introduce the concept of
subjectivity (Alexander et al., 2010; Morse et al., 2001) in the form
of expert judgment. However, no hazard identiﬁcation method has
included the quantiﬁcation of this judgment. Consequently, the
pharmaceuticals chosen for investigation in environmental studies
are usually not justiﬁed (Conley et al., 2008; Santos et al., 2009),
except perhaps brieﬂy (Carballa et al., 2008; Lofﬂer et al., 2005).
Here, we propose a methodology to quantify and rank the
relative hazard of pharmaceuticals. Hazard is calculated from an
aggregation of different physico-chemical and toxicity criteria
deﬁning the drugs. Uncertainty in the criteria values is taken into
account by considering them as uniform random variables within
the range of values existing in the literature. Weights are assigned
to quantify the subjectivity introduced by the relative inﬂuence of
the different criteria used in the hazard assessment procedure.
These weights are considered to be random variables extrapolated
from an expert committee judgment. For this, the discrete choices
of the decision makers (DMs) are converted into continuous
probability density functions (PDFs) by kernel density estimation.1 http://ec.europa.eu/environment/chemicals/, site last accessed on 12.09.2011.This statistical technique enlarges the spectrum of weights that can
be assigned to criteria, which is valuable when the number of
experts is limited (Bowman and Azzalani, 1997).
The ﬂexibility of the method makes possible adjustment of the
classiﬁcation depending on the priorities of decision makers. Two
sets of weights are used: one giving priority to the protection of the
aquatic environment and the other to human health. They are
compared with the default ranking, deﬁned as giving equal weight
to each priority. The methodology is applied to a list of widely
consumed pharmaceuticals in Switzerland. As a result, we propose
an ordinal ranking of a list of pharmaceuticals whose consumption
may lead to long term environmental impacts.
2. Materials and methods
The general structure of the methodology is illustrated in Fig. 1.
First, the choice of substances and relevant criteria used in this study
is justiﬁed. Following this preliminary part, we present the different
steps of the ranking methodology. Weights are used to reﬂect the
relative subjective importance each criterion has in hazard quanti-
ﬁcation. Criteria and weights are expressed in terms of random
variables, the PDFs of which characterize their uncertainty. A utility
function is deﬁned and later used to aggregate criteria based on
their respective weights. Based on this utility function, a ranking of
the hazard for the investigated substances is deduced.
2.1. Choice of relevant parameters for hazard assessment
The hazard was evaluated for 58 pharmaceuticals. These were
selected because they are either among the most consumed in
Switzerland, or are usually considered as hazardous (Perazzolo
et al., 2010). Five criteria are used to describe each chemical:
 PNEC (Predicted No Effect Concentration): The PNEC is a well-
known parameter used in ecotoxicology to evaluate the hazard
of a substance (Bound and Voulvoulis, 2004; Carlsson et al.,
2006; Cooper et al., 2008). It is the concentration below which
exposure to a substance is not expected to cause adverse effects;
 Log Kow: This is the octanol/water partition coefﬁcient. In
ecotoxicology, it is usually used for estimating the bio-
accumulation potential of a substance (Bound and Voulvoulis,
2004; Carlsson et al., 2006; Perazzolo et al., 2010);
 Solubility: Maximum solubility of the substance in water;
 SLTC (Speciﬁc LongTermConcern): The SLTCestimates long term
effects of a substance, such as being carcinogenic, mutagenic,Fig. 1. Schematic presentation of the distance ranking procedure. Expert judgment
inﬂuences the deﬁnition of relevant criteria and their weights. The utility function is
computed 105 times so that expected values are calculated from all weights and
criteria combinations possible.
Fig. 2. Vectorial representation of a pharmaceutical’s physico-chemical characteristics.
The ﬁve criteria C1eC5 are described in the text.
Fig. 3. Illustration of extrapolation of discrete DM choice to continuous PDF using
Kernel smoothing density estimate. A similar plot is obtained for each of the criteria.
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to foster bacterial resistance (typically antibiotics. These
substances were listed by Kummerer (2001) and, in contrast to
other criteria, are given as binary values (unity for substances
with speciﬁc long term concerns and zero otherwise);
 TD (Therapeutic Dose): The dose that is estimated to produce
the desired therapeutic effect. The TD is commonly used as an
indicator for human toxicity, as proposed byWebb et al. (2003).
These ﬁve criteria lead to ﬁve parameters for each chemical,
which are collected into ﬁve-element vectors, P (C1, C2, C3, C4, C5)T,
as presented in Fig. 2 The numerical values of all parameters were
taken from Perazzolo et al. (2010).
The parameters in P have different ranges and dimensions. Thus,
each parameter is normalized according to:
Cnormalized ¼
C  Cmin
Cmax  Cmin
: (1)
Here, C is the parameter to be normalized, and Cmin and Cmax are,
respectively, the parameter-speciﬁc minimum and maximum
values of C. In all cases, values of Cnormalized near zero indicate a low
hazard, while high hazard is given by Cnormalized near unity.2.2. Uncertainty estimation
2.2.1. Quantiﬁcation of uncertainties in criteria
The parameters in P (Fig. 2) are subject to uncertainty (e.g.,
measurement error), i.e., Ci, i ¼ 1,.,5, are considered as indepen-
dent random variables, each with an associated PDF, fi. Because the
PDFs are unknown, here each fi is deﬁned as a uniform distribution
in the interval [0.8Ci, 1.2Ci]. This corresponds to a 20% uncertainty in
each criterion and thereby allows consideration of uncertainties
that exist in toxicological parameter measurements. Note that it is
also widespread to use a Gaussian PDF to describe measurement
uncertainties (BIPM, 2008). However, here we here estimate the
uncertainty not from direct measurements, but from values found
in the literature. Thus, the uniform distributionwas chosen because
it keeps parameters within a reasonable range, without giving
preference to one study or another. The methodology does not rely
on the assumptions used at this step and, depending on the data
used, different PDFs would be feasible.
2.2.2. Conversion of discrete preferences into continuous PDFs
Identiﬁcation of criteria that contribute to hazard level evalua-
tion, as well as quantifying relevant parameters, are not in them-
selves sufﬁcient to deﬁne a ranking procedure (Alexander et al.,
2010; Morse et al., 2001; Rashid and Hayes, 2011). Hazard ranking
varies depending onwhat the stakeholders arewilling to protect and
to tradeoff. Ranking can be based on considerations of human health
or aquatic ecosystems, for example. Each ranking will, however, be
based on the same parameters, although the parameters will be
weighted differently according to the target of the assessment.
Multi-criteria decision-making is performed with stakeholder
involvement (Sorvari and Seppälä, 2010) in order to determine theweighting applied to each parameter (Aragonés-Beltrán et al.,
2009; Lithner et al., 2011). This step is thus part of our ranking
procedure. A group of experts was asked, for each substance, to
rank the proposed criteria according to their assessment of rele-
vance to (i) environmental impact and (ii) human health. Multiple
methodologies can be used to elicit judgments from each individual
expert (Howell and Honey, 2010; Sorvari and Seppälä, 2010). For
reasons of practicality, ﬁve experts were approached indepen-
dently. Speaking more generally, however, deﬁnitive guidelines on
the number of experts involved in the consultation are not avail-
able, particularly if the number depends upon the perceived level
and variability of expertise per domain (Walls and Quigley, 2001).
Indeed, the number of experts can range from 3 to more than 80
(Bolger andWright, 1994). Again, our methodology does not rely on
the number of experts consulted.
Each of the ﬁve experts consulted proposed an ordinal ranking
for the elements of P. The experts’ ranks were binned to create
histograms of the rankings. These discrete distributions were con-
verted to continuous PDFs to permit consideration of a larger spec-
trum of weighting possibilities, and thus to capture better the
heterogeneity of experts’ viewpoints. Moreover, this conversion
allowsextrapolation/smoothingof theweighting values to cases that
may not be invoked due to the limited number of experts usually
available. It should be noted that, if a large pool of expertswere used,
then the conversion to a continuous PDF has minimal impact.
The kernel density estimation method was used to convert the
discrete histograms into continuous PDFs (Bowman and Azzalani,
1997). An application of the methodology to a synthetic histogram
is illustrated in Fig. 3. Thus, we obtained ﬁve PDFs, one for each
criterion’s weight, which relate the diversity of the DMs’ choices.
We name these functions gi, i ¼ 1,.,5, each one being associated,
respectively, with parameter Ci. The weight of each criterion is
thus a random variable, ji, deﬁned by its associated PDF gi. The
ﬁve ji values were grouped into the weight vector W.2.3. Utility score computation from criteria aggregation
For each chemical, the function u (P, W) is used to aggregate
together criteria. The utility function used was based on the
weighted Euclidian distance, deﬁned as:
uðP;WÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP5
i¼1
ðCijiÞ2
s
with
P5
i¼1
ji ¼ 1:
(2)
By construction, 0  u  1, with hazard increasing with
increasing u. In Eq. (2), weights are selected randomly and inde-
pendently in their respective distribution. The sum of the weights
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appropriately. Thus, each of the weights quantiﬁes the relative
contribution of its associated criterion to the multi-criteria hazard
estimation.
The expected value of u is given by:EðuðP;WÞÞ ¼
Z
/
Z ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX5
i¼1
ðCijiÞ2f1ðC1Þ.f5ðC5Þg1ðj1Þ.g5ðj5ÞdC1.dC5dj1.dj5:
vuut (3)Computation of Eq. (3) was performed using a Monte Carlo
approach, in which the Ci and ji values were selected randomly
from their respective distributions, fi and gi, after which the utility,
u, in Eq. (2) was calculated. By repeating this calculation many
times (here, 105), we obtained the distribution for u (P, W), the
mean of which corresponds to the expected value. Thus, from
Eq. (3) the expectation, denoted by E (u (P, W)), was calculated for
each of the 58 pharmaceuticals, with the hazard ranking deter-
mined by the values obtained.
As noted above, the experts ranked the pharmaceuticals
according to three different perspectives. The computation of
E (u (P, W)) was repeated for the three different sets of weights,
giving three ranked lists of pharmaceuticals. These results are
compared in the following section to evaluate the stability of the
methodology with respect to the different sets of weights
considered.Fig. 4. PDF of criteria weights when the target is the environment.2.4. Stability of the ranking
Three sets of weights were tested in our approach: one giving
priority to protection of the aquatic environment, another assessing
the hazard to human health, and ﬁnally, one assigning equal weight
to each criteria. Here, we provide a means to compare the differ-
ences in the rankings obtained for the different sets of weights. For
example, a substance that is safe for human health and highly
hazardous for the environment will have very different rankings.
This difference in rankings is quantiﬁed by the dispersion of ranks,
which in this work was estimated using the Gini index, D. This
coefﬁcient can be formulated in many different ways and is here
deﬁned as:
DðRÞ ¼ 4ðN  1Þn2  jsinðnp=2Þj
Xn1
k¼1
Xn
l¼ kþ1
dkl (4)
where N is the number of substances in the list, dkl refers to
the distance between the rank value R of one substance in one set of
weights (set number k), to the other set of weights (set number l)
(1  k  n  1 and k þ 1  l  n), n being the number of
different perspectives considered (here, n ¼ 3). Thus, dkl can be
expressed as:
dkl ¼ jRk  Rlj
with 1  k < n 1 and kþ 1  l  n: (5)
The Gini index given by Eq. (4) is by far the most frequently used
index in data dispersion studies (Cressie, 1991). The expression
used in this work presents the advantage that values are normal-
ized so that highest dispersion index possible is unity (see
Appendix A for details).D (R) was calculated for all 58 pharmaceuticals for the three
different sets of weights investigated. This measure of statistical
dispersion has a possible minimum of zero, a value that occurs
when the compared rankings are identical. Thus, small values of the
Gini index occur when the substance has a consistent ranking ineach of the considered perspectives. In contrast, values closer to
one indicate that the substance’s rank is highly dependent on DMs’
classiﬁcation.
3. Results and discussion
3.1. Expert judgment evaluation
Expert judgment evaluation used only a limited number of
DMs, but it serves here primarily to illustrate the methodology.
Experts ranked the importance of the physico-chemical criteria to
assess the hazard of pharmaceuticals to (i) the aquatic environ-
ment, and (ii) to human health. As explained previously, the
discrete choices of the DMs were converted into a continuous
weight functions. These functions are illustrated in Fig. 4 for (i)
and in Fig. 5 for (ii).
If one seeks to assess hazard for the environment then, as can be
seen in Fig. 4, PNEC and Log Kow are the two parameters that have
the highest probability of being heavily weighted. That is, among
the proposed physico-chemical criteria, these were estimated as
most important by the DMs in terms of environmental hazard. The
spread of the curves convey the disagreement among the DMs for
each criterion. The maximum solubility, in contrast, was not
considered to be of major importance for environmental hazard.
The PDFs for the SLTC and TD criteria have similar shapes in
Fig. 4. In contrast, as seen in Fig. 5, they were considered to be
important by the DMs to assess the hazard for human health.
Ideally, a human PNEC or an admissible daily intake (ADI) would be
a better estimate of toxicity, but they are largely unknown for
pharmaceuticals (Cunningham et al., 2009). For this reason, the TD
and SLTC have been used in different studies as an indicator of
pharmaceutical hazard for human beings (Cunningham et al., 2009;
Webb et al., 2003).
Note that the goal of this study is not to give single values of the
weights (and one could argue whether they exist) for the different
criteria, but rather to provide amethod that allows quantiﬁcation of
the variability that can exist among a group of DMs according to
Fig. 5. PDF of criteria weights when the target is human health.
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assessment.3.2. Pharmaceutical hazard ranking
Results for the different rankings obtained with the three
different sets of weights (priorities) are presented for the 20 most
hazardous substances in each ranking in Table 1. To evaluate in
what proportion the priority inﬂuences the ranking, the Gini index
is given for each of the substances, which we recall is a measure of
consistency between the three priorities. The ranking for phar-
maceuticals like ethinylestradiol, testosterone or erythromycin A is
very stable, these substances being at the top of the three different
rankings and thus presenting low Gini indexes (respectively 0, 0.04
and 0.07). On the other hand, substances like methotrexate,
ciproﬂoxacin, cyclophosphamide, norﬂoxacin, mitomycine, iopro-
mide and iopamidol show a very high dispersion in their ranking,
with Gini indexes higher than 0.4. This means that whether these
substances are considered hazardous (compared with others)
depends strongly on what target is considered by DMs. We can
observe in Table 2 that levetiracetam is the pharmaceutical that
obtains the highest dispersion score, with a Gini index value of 0.58,Table 1
Ranking of pharmaceutical hazard for the three priorities considered (only the
highest 20 of the 58 substances are presented). The Gini index is given into brackets
for each substance.
Rank Environment Human health No priority
1 Ethinylestradiol (0.00) Ethinylestradiol (0.00) Ethinylestradiol (0.00)
2 Fenoﬁbrate (0.23) Testosterone (0.04) Testosterone (0.04)
3 Tiagabine (0.23) Erythromycin A (0.07) Erythromycin A (0.07)
4 Testosterone (0.04) Cortisone (0.18) Norﬂoxacine (0.58)
5 Fluvastatin (0.21) Sulfamethoxazole (0.33) Cortisone (0.18)
6 Gemﬁbrozil (0.21) Amoxicillin (0.33) Sulfamethoxazole
(0.33)
7 Erythromycin A (0.07) Ciproﬂoxacin (0.40) Amoxicillin (0.33)
8 Simvastatin (0.19) Cyclophosphamid (0.40) Ciproﬂoxacin (0.40)
9 Diclofenac (0.21) Norﬂoxacine (0.58) Cyclophosphamid
(0.40)
10 Irbesartan (0.18) Mitomycine (0.42) Mitomycine (0.42)
11 Ezetimibe (0.19) Methotrexate (0.53) Levetiracetam (28)
12 Bezaﬁbrate (0.19) Iopromide (0.54) Methotrexate (0.53)
13 Fluoxetine (0.21) Iopamidol (0.54) Iopromide (0.54)
14 Cortisone (0.18) Fenoﬁbrate (0.23) Iopamidol (0.54)
15 Ibuprofen (0.19) Tiagabine (0.23) Fenoﬁbrate (0.23)
16 Ciproﬁbrate (0.19) Fluvastatin (0.21) Tiagabine (0.23)
17 Citalopram (0.19) Gemﬁbrozil (0.21) Fluvastatin (0.21)
18 Cloﬁbrate (0.19) Simvastatin (0.19) Gemﬁbrozil (0.21)
19 Propranolol (0.19) Irbesartan (0.18) Simvastatin (0.19)
20 Celecoxib (0.19) Diclofenac (0.21) Irbesartan (0.18)as it is successively ranked 53, 46 and 11 with the three different
sets of weights tested. Thus, the theoretical maximum dispersion
index possible of 1 is not obtained in this study.
The experts consulted in this study are considered as repre-
sentative of the DM population, so a study that would investigate
the effects of pharmaceuticals on, for example, the aquatic envi-
ronment would focus speciﬁcally on pharmaceuticals like fenoﬁ-
brate, tiagabine, ﬂuvastatine, simvastatine and diclofenac. This
result is in agreement with those of Perazzolo et al. (2010) and
Carlsson et al. (2006). Diclofenac has been found regularly in
surface water (Carballa et al., 2007; Cunningham et al., 2009;
Langford and Thomas, 2009; Santos et al., 2009), and as a conse-
quence is expected to be considered as a tracer substance by
authorities to indicate the occurrence of pharmaceuticals in the
environment in Switzerland (OFEV, 2009). On the other hand, for
investigating the potential effects of drug residues in potable water
on human health, effort should be directed towards different
substances like cortisone, sulfamethoxazole, amoxiciline or cipro-
ﬂoxacin. Moreover, due to their speciﬁc toxic characteristics (very
low PNEC, very low therapeutic dose and potential long term
effects), the hormones ethinylestradiol and testosterone, along
with the antibiotic erythromycin A should be in all cases included
in hazard assessment methodologies and regular measurement
campaigns.
This hazard ranking methodology complements that of Carlsson
et al. (2006). It is, to our knowledge, the only alternative method-
ology available for pharmaceutical hazard ranking. Carlsson et al.
(2006) expressed the hazard for a list of pharmaceutical
substances based on European legislation (European Commission,
2006), which as already mentioned assigns pharmaceuticals into
two groups entitled “Dangerous for the environment” or “Not
dangerous for the environment”. This categorization lacks infor-
mation on the relative hazard of any two substances belonging to
the same group. Among the substances considered in the study of
Carlsson et al. (2006) as dangerous to the environment, the one that
gets the lowest rank in the methodology presented here is meto-
prolol, with a rank of 39 (Table 2). This suggests that all substances
ranked higher than 39 in our ranking are potentially hazardous for
natural ecosystems.3.3. Limits and perspectives of the methodology
The hazard rankings proposed in this study were established
from a limited number of criteria and DMs. These limited numbers
(ﬁve criteria and ﬁve DMs) were dictated by data availability on
pharmaceutical properties, time, and DMs’ availability. In this
application, criteria values are identiﬁed for all substances. It is
common to ﬁnd ranking methodologies based on incomplete
datasets but introduction of bias in this case is inevitable (Cooper
et al., 2008; Kumar and Xagoraraki, 2010; Sanderson et al., 2004).
In case more parameters are available for more pharmaceuticals,
this work has the beneﬁt that it can be easily and rapidly adapted
while keeping the same computational framework.
In this work, the relative hazard for a list of drugs is estimated,
but this does not give information about the absolute hazard of
each substance. As a consequence, it cannot be used to afﬁrm or
refute any potential effect a substance can have on the environ-
ment. Instead, its goal is to compare the potential hazard of phar-
maceuticals to different targets, in order to choose which ones
require more detailed study in terms of the evaluation of their
absolute hazard. If a given substance is deﬁned as hazardous by
numbers of toxicologists and ecotoxicologists, it is likely that all
substances that have obtained a higher rank in the relative hazard
evaluation of this study can be considered likewise.
Table 2
Complete list of pharmaceuticals considered in this study. The table shows the hazard ranks for the three different priorities considered (Env e Environment, Hum e Humans, and no weighting). The Gini index provides
information about the consistency of the hazard ranking across the three priorities. The Gini index varies between 0 and 1, with values close to 0 implying a consistent ranking across all possible ranks.
Name Rank Env Rank Hum Rank no weight Gini Name Rank Env Rank Hum Rank no weight Gini
Acébutolol 42 44 46 0.07 Ibuprofene 15 24 26 0.19
Valproic acid 28 35 37 0.16 Iopamidol 44 13 14 0.54
Acipimox 54 50 24 0.53 Iopromide 43 12 13 0.54
Allopurinol 55 55 55 0.00 Irbesartan 10 19 20 0.18
Amoxicillin 25 6 7 0.33 Labetalol 26 33 35 0.16
Atenolol 52 54 54 0.04 Lamotrigine 31 36 38 0.12
Bezaﬁbrate 12 22 23 0.19 Levetiracetam 53 46 11 0.74
Bisoprolol 40 43 45 0.09 Mesalazine 46 47 48 0.04
Carbamazepine 32 37 39 0.12 Metformin 58 58 58 0.00
Celecoxib 20 28 31 0.19 Methotrexate 41 11 12 0.53
Ciproﬁbrate 16 25 27 0.19 Metoprolol 39 42 44 0.09
Ciproﬂoxacin 29 7 8 0.40 Mitomycin 34 10 10 0.42
Citalopram 17 26 28 0.19 Morphine 48 49 50 0.04
Cloﬁbrate 18 27 29 0.19 Nadolol 49 51 51 0.04
Clonazepam 33 38 40 0.12 Naproxen 23 32 34 0.19
Cortisone 14 4 5 0.18 Nebivolol 22 31 33 0.19
Cyclophosphamide 30 8 9 0.40 Norﬂoxacin 37 9 4 0.58
Diazepam 27 34 36 0.16 Oxprenolol 38 41 43 0.09
Diclofenac 9 20 21 0.21 Pravastatin 36 40 42 0.11
Erythromycin A 7 3 3 0.07 Pregabalin 45 45 47 0.04
Ethinylestradiol 1 1 1 0.00 Primidone 47 48 49 0.04
Etoﬁbrate 21 30 32 0.19 Propranolol 19 29 30 0.19
Ezetimibe 11 21 22 0.19 Salicylic acid 35 39 41 0.11
Felbamate 50 52 52 0.04 Simvastatin 8 18 19 0.19
Fénoﬁbrate 2 14 15 0.23 Sotalol 51 53 53 0.04
Fluoxetine 13 23 25 0.21 Sulfamethoxazole 24 5 6 0.33
Fluvastatine 5 16 17 0.21 Testosterone 4 2 2 0.04
Gabapentine 57 57 57 0.00 Tiagabine 3 15 16 0.23
Gemﬁbrozil 6 17 18 0.21 Topiramate 56 56 56 0.00
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Thousands of pharmaceuticals are produced and consumed
each year. Many of them could reach the environment. But, only
a restricted list of substances can be investigated in detail due to
laboratory capacities, time available, legislation, and budgetary
constraints. The selection of substances of interest can be greatly
inﬂuenced by the goal of the study.
For a study that would investigate the effects of pharmaceu-
ticals on the aquatic environment, speciﬁc substances of interest
have been identiﬁed to be fenoﬁbrate, tiagabine, ﬂuvastatine,
simvastatine and diclofenac. On the other hand, for a study
concerning the potential effects of traces of drugs in potable
water on human health, investigation efforts should be directed
towards other substances like cortisone, sulfamethoxazole,
amoxiciline or ciproﬂoxacin. In addition, because they possess
speciﬁc toxic characteristics (very low PNEC, very low therapeutic
dose and potential long term effects), the hormones ethinyles-
tradiol and testosterone, along with the antibiotic erythromycin A
should be in all cases included in risk-assessment methodologies,
environmental concentration estimates and regular measurement
campaigns.
As this study intends to deﬁne relative hazard for pharmaceutical
substances and not risk, it can be generalized without consideration
of time and space. It is so far the only ranking methodology of
pharmaceuticals that allows the integration of the dispersion of
stakeholders’ diversity of point of views within one ranking.Appendix A. Normalization of Gini index
In Eq. (4) consider only the sum:
D ¼
Xn1
k¼1
Xn
l¼ kþ1
dkl; (A.1)
where dkl is the difference between rank values R for the different
sets of weights, so:
dkl ¼ jRk  Rlj with 1  k < n and k < l  n: (A.2)
Assume that the sets of weights have been ordered such that
Rl  Rk, then dkl ¼ Rl  Rk.
After simpliﬁcation we get:
D ¼
Xn1
k¼1
Xn
l¼ kþ1
dkl ¼
Xn
k¼1
Rkð2k 1 nÞ (A.3)
In the sum
Pn
k¼1Rkð2k 1 nÞ, the factor of 2k  1  n is:
 negative for k < (n þ 1)/2 if n odd, k < (n þ 2)/2 if n even, and,
 positive for k  (n þ 1)/2 if n is odd, k  (n þ 2)/2 if n is even.
Thus, to ﬁnd largest possible D, set Rk ¼ 0 for k 
ðnþ 1þ jcos ðnp=2ÞjÞ=2. Then the maximum of D is obtained
by taking Rk ¼ N  1 for k  ðnþ 1þ jcosðnp=2ÞjÞ=2.
So, the maximum possible D is:
D ¼ ðN  1ÞP n
k¼ nþ1þjcosðnp=2Þj2
ð2k 1 nÞ
¼ ðN  1Þn
2  jsinðnp=2Þj
4
(A.4)
If we wish to have 0  D  1 in Eq. (4), then the leading, coef-
ﬁcient should be 4=ðN  1Þðn2  jsinðnp=2ÞjÞ.References
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